Cohesive corporate advice across jurisdictions

Our international corporate team has the capability, resources and experience to manage transactions efficiently and quickly. Our relationship-driven approach means that when you work with us, you'll benefit from our market intelligence, specialist industry knowledge and commercial business solutions. With specialists in all areas of corporate law, we're known for being a strong mid-market player that is pushing into larger transactions.

"All of our matters cut across jurisdictions, yet Osborne Clarke deals with them in a clear and concise manner."

Corporate/M&A: £100-800 million client, Chambers and Partners

How we can help you

Our experts can advise on all aspects of your company's journey, helping you make the most of opportunities and challenges. The core of our work is M&A, venture and private equity. We work across a range of sectors, including tech, media and comms, financial services, real estate, life sciences and healthcare.

Mergers and acquisitions

We have M&A capability of real scale and are a forerunner in mid-market mergers, acquisitions and takeovers of listed companies. Our large international team allows us to group our specialist lawyers across sector lines and get involved in the most dynamic opportunities. We work at the cutting-edge of M&A law for private and public organisations.

Private equity

Our large team advises those who are seeking investment and debt providers on all aspects of private equity. We are often involved in the initial transactions of an investment and have expertise in buy-outs, bolt-on/roll-up acquisitions and exits. Our clients include sponsors, management teams, corporates and institutional investors.

Venture capital

We act across the full spectrum of venture transactions and funding rounds, from early-stage and seed funding (including spin-outs) all the way to exit. We have a focus on later-stage funding rounds.

Growth capital

Our lawyers support growth– no matter what is needed. We work with clients to assess the risk of making or receiving an investment into an established company and develop a strategy to help keep their returns on track.

International expansion

Our international expansion team guides fast-growing and innovative businesses at every stage of their journey. We work with clients from the first stages of expansion to scaling global markets, including setting up branch offices and subsidiaries and developing an international branch structure.

Joint ventures

Our joint venture expertise will help you to enter or expand into new markets, develop new products or reinforce relationships between suppliers and customers. We advise on all aspects of domestic and international agreements.

Corporate reorganisation and simplification

Our team provides an integrated end-to-end solution to our client's reorganisation and demerger needs. We help our clients decrease risk and compliance burden, facilitate acquisitions and disposals, make the most efficient use of cash resources and future-proof their group.

Equity capital markets

We advise issuers, financial institutions and other market participants on all aspects of equity capital markets transactions. Our expertise includes initial public offerings on local and international stock exchanges and follow-on offerings, including placings, rights issues, open offers and capitalisations. We also work with private and public organisations on take-private transactions.

Investment funds

Our investment funds team is ranked amongst the best and our advice will always look beyond your first investment. We're experienced in all types of fund structures and strategies, including private equity, real estate, venture capital, hedge, retail, infrastructure and natural resources.

Corporate governance and ESG

We can support you with all your governance, compliance and ESG considerations, drawing on our international expertise to ensure you meet the requirements in all of the jurisdictions where you do business. Our clients include B Corp businesses and businesses that are working towards certification.

Company secretarial

Our company secretarial team will make sure that you are on top of your legal and administrative obligations. We offer some fixed fee services, where we will take care of all essential compliance work. We also offer different and bespoke services in each jurisdiction.

Legal tech solutions

We also use technology and various AI services to deliver deal efficiency and cost-effectiveness. OC Solutions provides a single source of truth to manage corporate transactions. It brings all of the deal information together in one intuitive location. This means that when you work with us, you will have real-time deal data at your fingertips.

"Osborne Clarke provide expert and clear advice based on a deep understanding of the commercial and legal issues. The strength and depth of their teams is evident across the firm; technical expertise combined with strong commercial awareness and good interpersonal skills."

Corporate Client, Legal 500

Our international corporate lawyers

We have corporate lawyers in the UK, Germany, France. Italy, Poland, Sweden, Spain. the US, The Netherlands, Belgium, Singapore and China. They work together to provide cohesive advice across Europe, the US and Asia.

Many of our clients come to us for domestic work, as well as domestically generated work with international cross-border dimensions. We have a deep specialism in advising on inbound European transactions.

Our portfolio of clients includes fast-growing businesses and those with a tech focus. We are the legal advisor of choice for future-focused clients and organisations at the forefront of innovation and transformation in their market. We have particular expertise in the life sciences and healthcare, energy and utilities, and tech, media and comms sectors.


Portfolio Group

An all-service platform: supporting investors and management teams to realise the potential of their investments

Portfolio Group

Osborne Clarke’s Portfolio Group is an all-service platform supporting investors and management teams to realise the potential of their investments.

We advise on strategic value add projects, minimising legal and regulatory risk, as well as business as usual matters.

With a deep understanding of the framework in which institutionally-backed companies operate, we can support you in taking advantage of the opportunities - as well as navigating the constraints - that framework brings.




Advised German immunotherapies developer and manufacturer BionTech on its acquisition of pioneering AI-powered drug discovery and development company InstaDeep.


Advised Brompton on a £19m investment by BGF and other shareholders.


Advised on the investment in Nutrisure by Lonsdale Capital.

Lloyds Development Capital

Advised on the £140m AIM IPO of Joules Group plc.

Investec Bank

Advised on on the £50m AIM IPO of Blue Prism Group plc.

Cantor Fitzgerald Europe

Advised on the £70m AIM IPO of Stride Gaming plc.

FeverTree Drinks plc

Advised on its £154m AIM IPO.

Chamartín Meermann Immobilien AG

Advised on  its €80m IPO on the Frankfurt Stock Exchange.

Media[netCom] AG

Advised on its €40m IPO on the Frankfurt Stock Exchange.

Tribal Group plc

Advised on its £42m rights issue, disposal of its Synergy business and move to AIM.

Investec Bank

Advised on the £20m placing by Johnson Services Group plc.

Canaccord Genuity

Advised on the £18m placing by Goals Soccer Centres plc.

Panmure Gordon

Advised on the reverse takeover of Eclectic Bar Group plc.

UNITE Group plc

Advised on its £100m placing and open offer.

Bridges Ventures LLP

Advised on the formation of Bridges Property Alternatives Funds III (2015) and IV (2016).

Foresight Group LLP

Advised on the launch of its second regional investment fund, an LP fund targeting £60m in commitments for private equity investment into the North West of England, with the backing of various local government pension schemes in the region.


Advised on all aspects of structuring and establishment of the Niam Nordic VI closed-ended real estate fund with equity commitments of €800 million.

Carphone Warehouse

Worked to establish a £2.2 billion joint venture with American retailer Best Buy, and later worked to unwind the venture when Carphone Warehouse bought out its partner.


Advised Ermewa, the freight asset management subsidiary of SNCF, the French national rail operator, on its sale of 50% of the shares of its wholly-owned locomotive operator Akiem to Deutsche Asset & Wealth Management, allowing Akiem to improve its fleet and expand further.

British Waterways and Canary Wharf Group

Helped the two companies establish the Wood Wharf Limited Partnership, which opened up land in London’s Canary Wharf to new development.

NoHo Film and ITV

Advised on the formation of a joint venture TV production backed by ITV Studios, one of the UK’s largest television production companies.


Advised a joint venture between National Grid and 20C on its projects to exploit renewable energy in the natural gas transmission network.


Advised online collaboration business Acano on its $700m acquisition by Cisco systems.

Cloud Talent

Advised strategic cloud consulting business Cloud Talent on its sale to Avanade.

Iris Worldwide

Advised international agency networki on its sale to Cheil Worldwide, Inc.


Advised the selling shareholders and management team on the auction sale process leading to an MBO backed by LDC who invested £37.5m alongside £55m of senior debt provided by RBS valuing the business at £105m.


Advised fintech business IDScan on its £45m sale to GB Group Plc.

Time Inc

Advised Time Inc. (UK) on their acquisition of digital creative advertising business, Collective Europe Limited from Collective Inc.

Majestic Wine

Advised Majestic Wine on its £70m acquisition of Naked Wine.


Advised Rotork on its acquisition of the Bifold Group Ltd from private equity house LDC for up to £125m on a cash-free, debt-free basis.

Actavis UK and Acatvis Ireland

Advised Actavis UK Limited and Actavis Ireland Limited on its proposed £603m divestment by Teva Pharmaceutical Industries Ltd to Intas Pharmaceuticals Ltd.


Connect with one of our experts